Two No­var­tis sites stop man­u­fac­tur­ing can­cer ther­a­pies af­ter qual­i­ty is­sues

Af­ter find­ing some qual­i­ty is­sues at­trib­uted to its man­u­fac­tur­ing process, No­var­tis has halt­ed the pro­duc­tion of two of its ra­di­oli­gand ther­a­pies at sites in Italy and New Jer­sey, the com­pa­ny an­nounced Thurs­day.

The pro­duc­tion of Lu­tathera and Plu­vic­to will stop tem­porar­i­ly at its sites in Ivrea, Italy and Mill­burn, NJ. The moves come out of “an abun­dance of cau­tion” af­ter some qual­i­ty is­sues were iden­ti­fied. Pro­duc­tion is ex­pect­ed to re­sume with­in the next six weeks, No­var­tis said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER